Research efforts are currently directed towards the development of S1P inhibitors that may be used in the treatment of dyslipidemia and a variety of cardiometabolic risk factors associated with diabetes and obesity [81]. The gene discussed is MBTPS1; the disease is obesity due to melanocortin 4 receptor deficiency.